Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the effectiveness of a dose-escalation
regimen (400 to 800mg bid) relative to the standard dosing regimen (400mg bid) of sorafenib
given in patients with metastatic RCC.
The secondary objectives are to evaluate the effects of the dose-escalation regimen on the
quality of life (QoL) of patients with metastatic RCC and to characterize the safety and
tolerability profile of a dose-escalation regimen of sorafenib in patients with metastatic
RCC.